Co-Diagnostics Inc (CODX)
$1.13
0.02 (1.74%)
CODX Stock Quote Delayed 30 Minutes
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
35.32M
PE Ratio
-0.93
EPS
-1.21
Volume (Avg. Vol.)
1,956
Day's Range
$1.13 - $1.15
52-Week Range
$0.98 - $1.89
Dividend & Yield
N/A (N/A)
CODX Stock Predictions, Articles, and Co-Diagnostics Inc News
Co-Diagnostics Stock Is a Buy Ahead of and After Earnings
Co-Diagnostics stock has emerged as a big winner from Covid-19. Testing for novel viruses may make it a long-term winner in the new normal.
Co-Diagnostics Is a Smart Way to Play Coronavirus Testing
Co-Diagnostics says its coronavirus tests are 100% accurate in tests in three countries, making CODX stock a smart play.
Co-Diagnostics Is Becoming More Relevant
A no-name investment in 2019, CODX stock has emerged as one of the most relevant players as Covid-19 diagnostics take center stage.
Steer Clear of Co-Diagnostics Stock and Its Multitude of Red Flags
CODX stock has risen tremendously so far this year. but the company is facing tough competition and has many red flags.
When It Comes to Coronavirus Investing, CODX Stock Is a Bad Bet
Many companies are vying to deliver the best coronavirus test. Co-Diagnostics is unlikely to be the ultimate winner in a crowded marketplace.
Testing-Kit Clearance Is the Green Light to Buy Co-Diagnostics
A fresh FDA approval means that CODX stock has full permission to clear its previous high mark.
Co-Diagnostics Stock Is an Interesting But Overpriced Pandemic Pick
Despite Co-Diagnostics' potential, a massive price run-up has made CODX stock much less attractive.
Co-Diagnostics Stock Is a Long-term Play in Disguise
As a near-term speculation, CODX stock might not be appropriate. But in the bigger picture, the coronavirus has taught harsh lessons to nearly every country, making Co-Diagnostics as relevant as it's ever been.
Why Virus-Play CODX Stock Isn’t a Long-Term Cure for Ailing Portfolios
While doubts abound on the various economic interventions in play or in plan, the same can’t be said for coronavirus-play CODX stock.
How High Can Virus Concerns Take CODX Stock?
Thanks to the need for coronavirus testing, CODX stock has plenty of upside potential – in the near term. Because of its likely ephemeral trajectory, be sure to have your finger on the trigger if you’re going to speculate on it.
Up 2000% on Coronavirus Worries, CODX Stock Is a Short-Term Buy
So long as coronavirus keeps spreading, CODX stock will keep working -- but the virus won't keep spreading forever.
